ORASIS PHARMACEUTICALS DOUBLES DOWN ON EYE CARE PROFESSIONALS, NOT TELEHEALTH, AS QLOSI® REFILLS REACH 49%¹

This is primarily a conversion-funnel story, not a clean demand inflection. The incremental value comes from reducing abandonment at the first prescription and collapsing the time between diagnosis and trial; that can make early script data look better than underlying willingness-to-pay. The key question over the next 1-2 quarters is whether persistence holds after the promotional layer rolls off, because that is what determines whether the product earns a durable spot in routine optometry workflows.

The more interesting second-order effect is channel control. Moving fill fulfillment into the exam room and a specialty hub shifts leverage away from retail pharmacy and toward the prescriber, which is usually good for brands with high patient education needs but bad for commoditized channels. If this model works, the moat is not just the molecule but the office workflow and data loop; that is a template competitors in presbyopia will have to match, whether they are branded incumbents or compounding substitutes.

The contrarian risk is that the market may overestimate how durable convenience-category adherence can be. Presbyopia is highly substitutable with readers and other low-friction fixes, so promo-driven starts can decelerate quickly once the patient hits standard pricing or any comfort/safety concern reappears. The real falsifiers are a drop in refill persistence below promotional levels, weaker payer access, or any signal that office dispensing is merely pulling forward demand rather than expanding it.